- Home
- SDHY vs MRVI Comparison
SDHY vs MRVI Comparison
Compare SDHY & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDHY
- MRVI
- Stock Information
- Founded
- SDHY 2020
- MRVI 2014
- Country
- SDHY United States
- MRVI United States
- Employees
- SDHY N/A
- MRVI N/A
- Industry
- SDHY Finance/Investors Services
- MRVI Biotechnology: Pharmaceutical Preparations
- Sector
- SDHY Finance
- MRVI Health Care
- Exchange
- SDHY Nasdaq
- MRVI Nasdaq
- Market Cap
- SDHY 415.2M
- MRVI 376.2M
- IPO Year
- SDHY N/A
- MRVI 2020
- Fundamental
- Price
- SDHY $17.02
- MRVI $2.89
- Analyst Decision
- SDHY
- MRVI Hold
- Analyst Count
- SDHY 0
- MRVI 9
- Target Price
- SDHY N/A
- MRVI $5.25
- AVG Volume (30 Days)
- SDHY 94.0K
- MRVI 933.6K
- Earning Date
- SDHY 01-01-0001
- MRVI 11-06-2025
- Dividend Yield
- SDHY 8.46%
- MRVI N/A
- EPS Growth
- SDHY N/A
- MRVI N/A
- EPS
- SDHY 1.07
- MRVI N/A
- Revenue
- SDHY N/A
- MRVI $219,830,000.00
- Revenue This Year
- SDHY N/A
- MRVI N/A
- Revenue Next Year
- SDHY N/A
- MRVI $7.23
- P/E Ratio
- SDHY $14.31
- MRVI N/A
- Revenue Growth
- SDHY N/A
- MRVI N/A
- 52 Week Low
- SDHY $13.93
- MRVI $1.67
- 52 Week High
- SDHY $15.50
- MRVI $9.50
- Technical
- Relative Strength Index (RSI)
- SDHY 56.29
- MRVI 54.43
- Support Level
- SDHY $16.89
- MRVI N/A
- Resistance Level
- SDHY $17.18
- MRVI $2.80
- Average True Range (ATR)
- SDHY 0.10
- MRVI 0.15
- MACD
- SDHY -0.01
- MRVI -0.05
- Stochastic Oscillator
- SDHY 43.10
- MRVI 98.63
About SDHY PGIM Short Duration High Yield Opportunities Fund
PGIM Short Duration High Yield Opportunities is a closed-end management investment company. The fund's investment objective is to provide total return, through a combination of current income and capital appreciation. Its seeks to achieve its objective by investing in a diversified portfolio of high yield fixed income instruments.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.